It is known that the administration of the NLRP3 inhibitors reduced the severity of the disease in AML [118], DLBCL [119], GvHD [120], multiple myeloma [121], and sickle cell anemia [122] in both vitro and in vivo studies. This evidence concerns the gene NLRP3 and diffuse large B-cell lymphoma.